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between rLR in 3TmMRI and the clinical variables, a logistic 
regression analysis was carried out. 
Results: In 14/57 patients (24.56%) a rLR through 3TmMRI 
was detected. Median pre-SRT PSA was 0.40 ng/ml 
(interquartile range, 0.30-2.05 ng/ml). The location of the 
recurrence was perianastomotic in 8/14 patients (57.14%) 
and retrovesical in 6/14 patients (42.86%). The median size 
of the local recurrence was 15.2 mm (range, 8.0-46.0 mm). 
The median apparent diffusion coefficient (ADC) value on 
DWI was 0.90 mm2/s (range, 0.35-1.58 mm2/s) and 6/14 
patients (42.85%) presented type 3 pathological captation 
curves and 3/14 patients (21.42%) presented type 2 
enhancement curves in the DCE images. Normal prostate 
tissue remains were identified in 9/57 patients (15.78%). 
Pelvic nodal recurrence was evidenced in 4/57 patients 
(7.01%) and pelvic bone metastasis were found in 4/57 
patients (7.01%). 12.90% (4/31) rLR was observed in patients 
with PSA ≤0.5 ng/ml, vs 38.46% (10/26) for PSA>0.5 ng/ml. 
The incidence of rLR according to PSA doubling time (PSADT) 
was 15.% (6/40) for PSADT≤14 months, vs 54.54% (6/11) for 
PSADT>14 months. The probability of rLR was significantly 
higher in patients with PSA levels >0.5 ng/ml (adjusted odds 
ratio (OR): 6.25; 95% confidence interval (CI): 1.27-
30.79;p=0.02), or PSA doubling time (PSADT)>14 months 
(adjusted OR: 7.12; 95% CI:1.40-36.25; p=0.01). 
Conclusions: This is the first study to find a significant 
relationship between the PSADT and the rLR through MRI. 
Patients that benefit most from conducting a 3TmMRI were 
those with PSADT>14 months or with pre-SRT PSA >0.5 ng/ml. 
Its routine use could have significant clinical implications in 
SRT.  
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Purpose/Objective: To eradicate all clonogenic cells within 
the gross tumor volume (GTV) and subclinical malignant 
disease area (CTV), for most cancers different radiation doses 
are prescribed to these volumes. This paradigm is however 
not routinely applied in prostate cancer. The entire gland is 
typically treated as GTV to a conventional dose of 78 Gy. 
Here, in higher risk patients, the treatment results are not 
sufficient, yet associated with mild to severe normal tissue 
toxicity. Derived from the histopathological properties, we 
propose to differentiate the dose between GTV and the CTV 
in the treatment of prostate cancer in order to increase the 
treatment results as well as reduce the risk of the treatment-
related toxicity.  
Materials and Methods: Twenty-five radical prostatectomy 
specimens were studied. The largest tumor focus was defined 
as index lesion. All index lesions and satellite tumor lesions 
≥0.5cm3 were set as GTV. The CTV was characterized as the 
whole gland excluding the GTV. Volume, cell density and 
Gleason score of index and satellite lesions were determined. 
This information was incorporated into radiobiological 
modeling of dose differentiation between GTV and CTV for 
these patients simulating the situation as if they were 
treated with radiotherapy. The tumor control probability 
(TCP) was modeled by assuming either a homogeneous or a 
heterogeneous α according to histopathological properties of 
tumor foci. For an α/β of 3, we chose the value for the 
homogeneous α (αhom) such that 80% TCP was reached in our 
population with a conventional dose of 78 Gy. The 
heterogeneous α varied with Gleason grade, keeping the 
weighted average over all tumors and Gleason grades equal 
to αhom. 
 
Results: 
 
 
Multifocal cancer was found in 76% (19/25) of the cases. The 
CTV of 12 cases of multifocal cancers (12/19) contained 
advanced pathology of GS 4+3 or 4+4. Compared to the GTV 
however, the pathology of CTV was on average more 
favorable. We found αhom=0.17 Gy-1 to reach 80% TCP with a 
conventional dose of 78 Gy. Here, a GTV dose of 81 Gy could 
be combined with a dose reduction to the CTV to 71 Gy 
without compromising the TCP in the population (Figure1a). 
Using a heterogeneous α however, α=0.212, 0.162 and 0.112 
Gy-1 for Gleason patterns 3, 4 and 5 respectively, a GTV dose 
of 89 Gy could be combined with a 70 Gy dose to the CTV 
while maintaining a TCP of 80% in the population (Figure1b). 
Conclusions: As subclinical prostate tumor foci may be 
clinically relevant, these need to be treated as CTV. If a 
homogeneous radiosensitivity for all tumor foci is considered, 
dose differentiation between GTV and CTV in the order of 10 
Gy may be feasible. Further dose differentiation can be 
achieved if Gleason grades are related to a heterogeneity in 
the radiosensitivity of the tumor foci. This may reduce the 
risk of the treatment-related toxicity without compromising 
local control. Further studies are needed to determine the 
effect of heterogeneous radiosensitivity on the response of 
individual patients to different regimes of radiotherapy.  
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Purpose/Objective: Knowledge about prostate cancer death 
(PCD) risks for an individual patient is essential to determine 
optimal treatment strategies. Long-term data from large 
prospective studies on this subject are scarce. The goal of 
our study was to reveal patterns and prognostic factors for 
PCD within established risk groups, using data from a clinical 
trial with long-term follow-up. 
Materials and Methods: Patients were treated (prostate, 
seminal vesicles) to 68 Gy or 78 Gy at daily fractions of 2 Gy 
in 1997-2002; 447 high-risk (HR) patients (≥T2c, PSA>20, 
and/or Gleason >7, according D’Amico), 90 low-risk (LR, T1-
T2b & Gleason ≤6 & iPSA ≤10) and 127 intermediate-risk (IR). 
Prognostic value of Gleason, iPSA, T stage, and baseline 
factors were evaluated, including pre-treatment patient-
reported GI and GU symptoms (questionnaire). Cox regression 
and Chi-square based risk classification trees were applied. 
For the latter the classified risk was PCD within 10y (yes/no). 
This classification method uses algorithms to create 
subgroups and cutoffs based on maximal distances between 
them. Cumulative incidences were calculated using Kaplan 
Meier analysis. 
Results: Median follow-up was 113 months. Prostate cancer-
specific survival (PCSS) at 10y was 97 % in the LR group (2 
cases of PCD), 93 % for IR (7 cases), and 74 % for HR (90 
cases, p<0.0001). Within the IR group, the classification tree 
identified 3 significantly different risk profiles for PCD < 10y: 
1) prostate volume ≤ 66 cc (0/62; 0.0 %), 2) volume > 66 cc & 
T1 (1/33; 3.0 %), and 3) volume > 66 & T2a/T2b (6/32; 18.8 
%). Cox regression confirmed that iPSA and Gleason had no 
prognostic value within the IR group. In the HR group, 
Gleason score <7 (n=171) was associated with a relatively low 
PCD risk (PCSS 91% at 10y, Figure 1A). For Gleason 7 (n=159) 
PCSS was 68% and for >7 (n=117) 57%. For HR - Gleason <7, 
the classification tree identified two risk profiles: 1) PSA ≤ 22 
(4/119; 3.4 %), and 2) PSA >22 (9/52; 17.3 %). For HR - 
Gleason ≥7 a risk of 10 % was identified for patients >74y 
(5/50). PCD risk for the remaining patients ≤74y and Gleason 
≥7 (n=226) appeared to be significantly associated with 
baseline reported GU symptoms of nocturia and straining, 
which was confirmed at Cox regression (nocturia p=0.003, 
straining p=0.005). PCSS at 10y in the latter group was 44 % 
in case of nocturia ≥4 and/or straining (n=65, 29 events) and 
67 % (n=161, 43 events) if these symptoms were absent 
(Figure 1B). 
 
 
 
Conclusions: Significant predictors for PCD were identified 
within the risk groups. Baseline GU symptoms were 
associated with aggressive and fatal disease for high-risk 
patients, suggesting that in these cases the symptoms are 
caused by tumor tissue. The HR subgroup with Gleason <7 & 
iPSA <≈20 (n=119, 27 % of HR) behaved as LR with a 10y PCSS 
of 96 %. IR patients with prostate volumes below 66 cc 
behaved as LR as well with a 10y PCSS of 100 %. Additional 
modeling and validation is needed for further interpretation 
of these findings. 
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Purpose/Objective: Assessing the main predictors of 
impotence 1 year after RT for prostate cancer (PCa).  
Materials and Methods: Within a multi-centric prospective 
study aimed to assess the predictors of GU toxicity and 
erectile disfunction after RT for PCa, 337 patients (pts) filled 
in the IIEF questionnaire before RT and were further 
requested to fill it in at the end of RT, and every 6 months up 
to 5 year from the end of RT. Based on IIEF questions 1-5 and 
15 (score range: 0-30, IIEFp), men were considered potent if 
IIEFp≥13: 155/337 pts were potent before RT and 90/155 did 
not receive any hormonal therapy (neo-adjuvant and/or 
adjuvant, HT-naive). At the time of analysis, 209/337 pts 
filled in the 1-year questionnaire and 53/209 were potent 
before RT and HT-naïve: moderate hypofractionation was 
used in 127/209 (2.35-2.7Gy/fr, 65-74.2Gy) while the 
remaining were treated with 1.8-2 Gy/fr (74-80Gy). Most pts 
were treated with IMRT (91%). Prospectively collected 
individual information (including age, BMI, comorbidities, use 
of drugs, previous surgery, smoke, HT, stage, PSA, GS, pelvic-
nodes RT) and D1% (as a surrogate of Dmax)/Dmean of the 
penile bulb (PB) contoured on the planning CT were available 
for this ad-interim analysis: D1%/Dmean were corrected into 
2Gy-equivalent doses using an alpha/beta =3 
(EQD2_1%/EQD2_mean). Predictors of 1-year potency were 
assessed through uni- and multi-variable backward logistic 
regression for the whole group and for the subgroup of 
potent, HT-naive pts.  
 
Results: In the whole group, potency at 1-year was predicted 
by a 2-variable model including pre-RT IIEFp (OR: 0.931, pvs 
EQD2_D1%. Best cut-off values based on ROC analysis showed 
that pre-RT IIEFp >22 and EQD2_D1% < or ≥ 74Gy respectively. 
The corresponding model taking the two dichotomized 
variables showed a higher AUC (0.78, 95%CI: 0.64-0.89): both 
variables were more robustly associated to impotency 
(EQD2_D1% ≥ 74Gy: OR: 8.7, p=0.004; IIEFp ≤ 22: OR: 
5.7,p=0.02).  
Conclusions: Despite the relatively small number of pts, our 
ad-interim results clearly showed that the dose to PB and the 
